Navigation Links
Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
Date:6/24/2013

NEW YORK, June 24, 2013 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announces that its technologies were featured at the American Diabetes Association annual meeting.

The presentations were made in part by members of Islet's Scientific Advisory Board, which included Dr. Jonathan Lakey, Dr. Kevan Harold and Dr. Eitan Akirav.   Sessions presented by Islet highlighted the following: 1) Circulating demethylated insulin as a potential early indicator of beta cell loss, 2) Immune therapy and type one diabetes previously discussed in the ADA journal 'Diabetes,' 3) New inhibitors to preserve and protect islet function, 4) Prolonged Euglycemia following transplantation of alginate encapsulated porcine islet cells, and 5) Consistency and scalability of young porcine islet isolation.

"We are excited to see that our technologies were accepted for presentation at the American Diabetes Association's annual meeting," said John Steel, Chairman and Chief Executive Officer of Islet Sciences. "This clearly provides further evidence for the value and promise for these technologies to be developed for treatments for diabetes and related complications."

"The technologies we have developed are groundbreaking and the recognition we continue to see from such well respected organizations such as the American Diabetes Association is extremely validating," stated Dr. Jonathan Lakey, Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences. The presentation of these technologies are another aspect to the value of our therapies which represents such a large market opportunity for the Diabetic community."

<
'/>"/>
SOURCE Islet Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
2. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
3. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
4. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
5. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
6. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
7. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
8. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
9. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
10. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
11. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Local veterinarian, Dr. Keith ... are seeking candidates to participate in an investigational study ... The ultimate goal of this study is to determine ... one or two arthritically affected joints can help reduce ... Candidates for the current investigational study must be older ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... For a biotech company, raising money is a saga that never ... do two things: execute on the timely achievement of key milestones ... of your next financing and where and who the money will ... in for a single round whereas most VCs usually commit for ...
...
... predicts the Alzheimer's disease drug market in ... by 15 percent annually for the next five ... entitled "Global Markets for Alzheimer's Disease Medications 2005," ... in an Alzheimer's drug market that generated more ...
Cached Biology Technology:Financing of biotech companies so far in 2005: A Midwest odyssey 2Financing of biotech companies so far in 2005: A Midwest odyssey 3Financing of biotech companies so far in 2005: A Midwest odyssey 4Financing of biotech companies so far in 2005: A Midwest odyssey 5Alzheimer's drug market to hit $5.5 billion by 2009, study says 2
(Date:8/31/2014)... One of the greatest challenges in modern medicine is ... but with minimal toxicity and side-effects to the patient. ... of the drug molecule. Ideally, the drug should have ... target, so that it binds it with high specificity. ... developed a synthetic amino acid that can impact the ...
(Date:8/31/2014)... Climate Change , suggests that if current trends continue ... global targets for total greenhouse gas (GHG) emissions in 2050. ... carefully about the food we choose and its environmental impact. ... one of a number of actions that need to be ... enough food for all. , As populations rise and ...
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4The early cost of HIV 2
... at Boulder team working at 16,400 feet in the ... retreating glacier ice can swiftly establish a thriving community ... alpine plants. The discovery is the first to ... one of the most extreme environments on Earth and ...
... choice all too frequently has come down to living ... indoor allergens. Today, The Clorox Company extends its ... Anti-Allergen Fabric Spray, a new product to help manage ... Clorox® Anywhere® Anti-Allergen Fabric Spray denatures dust mite ...
... Humans aren,t the only ones who like fatty foods - ... the Bearded Vulture Study and Protection Group in El Pont ... discard less energy-dense bones and choose only the bones containing ... to its young. His findings will be published this week ...
Cached Biology News:As Andean glacier retreats, tiny life forms swiftly move in, CU-Boulder study shows 2As Andean glacier retreats, tiny life forms swiftly move in, CU-Boulder study shows 3The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Scavenger birds chew the fat 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... Antibody to CRF The ... ovine CRF sequence that it ... fibres are found in the ... brain in colchicine treated 4% ...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Biology Products: